We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals

204 hedge funds and large institutions have $3.91B invested in Ionis Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 61 increasing their positions, 75 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

254% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 13

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

38% more capital invested

Capital invested by funds: $2.84B → $3.91B (+$1.07B)

18% more funds holding

Funds holding: 173204 (+31)

19% less repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 75

31% less call options, than puts

Call options by funds: $40.4M | Put options by funds: $58.5M

Holders
204
Holders Change
+31
Holders Change %
+17.92%
% of All Funds
6.61%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.16%
New
46
Increased
61
Reduced
75
Closed
13
Calls
$40.4M
Puts
$58.5M
Net Calls
-$18M
Net Calls Change
-$24.6M
Name Holding Trade Value Shares
Change
Change in
Stake
DY
26
Dowling & Yahnke
California
$25.4M -$2.99M -100,000 -13%
CCI
27
Columbus Circle Investors
$25.1M +$20M +668,418 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$24.5M -$46K -1,540 -0.2%
SNC
29
Stifel Nicolaus & Co
Missouri
$23.7M -$1.24M -41,639 -6%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$20.4M +$1.65M +55,385 +11%
TCIM
31
TIAA CREF Investment Management
New York
$20.2M +$480K +16,055 +3%
PAM
32
Panagora Asset Management
Massachusetts
$19.8M -$6.69M -223,810 -30%
Goldman Sachs
33
Goldman Sachs
New York
$19.8M +$2.69M +90,102 +21%
MG
34
Meditor Group
Bermuda
$18.4M -$896K -30,000 -6%
SAM
35
Sectoral Asset Management
Quebec, Canada
$16.6M +$13.2M +441,401 New
ICM
36
IronBridge Capital Management
Illinois
$14.2M +$11.3M +379,376 New
Allianz Asset Management
37
Allianz Asset Management
Germany
$13.8M -$21.8M -729,242 -66%
Invesco
38
Invesco
Georgia
$13.6M +$1.03M +34,611 +11%
BG
39
BlackRock Group
United Kingdom
$13.5M +$2.18M +73,122 +26%
Renaissance Technologies
40
Renaissance Technologies
New York
$12.3M +$8.99M +301,000 +1,078%
BIM
41
BlackRock Investment Management
Delaware
$11.9M +$559K +18,722 +6%
WHI
42
William Harris Investors
Illinois
$11.7M -$388K -13,000 -4%
EA
43
Emerald Advisers
Pennsylvania
$11.5M +$986K +33,018 +12%
OAM
44
Oxford Asset Management
United Kingdom
$11.2M -$1.87M -62,639 -17%
Charles Schwab
45
Charles Schwab
California
$11M -$3.66M -122,559 -30%
VanEck Associates
46
VanEck Associates
New York
$10.3M +$8.17M +273,413 New
CS
47
Credit Suisse
Switzerland
$10.3M +$693K +23,184 +9%
Dimensional Fund Advisors
48
Dimensional Fund Advisors
Texas
$9.89M +$16.2K +542 +0.2%
Millennium Management
49
Millennium Management
New York
$9.77M -$16.6M -554,185 -68%
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$9.49M -$1.48M -49,639 -16%

IONS Hedge Fund Activity: Q3 2013 in Review

204 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2013, worth a combined $3.91B — up 38% from $2.84B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new IONS positions and 13 closed out — a net gain of 33 holders — while 61 added to existing stakes and 75 trimmed.

The largest buyer was Artisan Partners, adding an estimated $43.9M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $29.9M.

  • 204 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2013, up from 173 in Q2 2013.
  • Funds reported $3.91B of Ionis Pharmaceuticals stock for Q3 2013, up 38% quarter-over-quarter.
  • 46 funds opened new Ionis Pharmaceuticals positions in Q3 2013 and 13 closed out, a net change of +33 holders.
  • The largest Ionis Pharmaceuticals buyer in Q3 2013 was Artisan Partners, an estimated $43.9M added.
  • The largest Ionis Pharmaceuticals seller in Q3 2013 was BNP Paribas Financial Markets, an estimated $29.9M sold.

Based on aggregated 13F filings for Q3 2013.